Immunogenicity and safety of a dengue vaccine given as a booster in Singapore: a randomized Phase II, placebo-controlled trial evaluating its effects 5–6 years after completion of the primary series. Issue 3 (3rd March 2020)

• Record Type: Journal Article
• Authors: Park, Juliana; Archuleta, Sophia; Oh, May-Lin Helen; Shek, Lynette Pei-Chi; Jin, Jing; Bonaparte, Matthew; Frago, Carina; Bouckenooghe, Alain
• Is Part Of: Human vaccines & immunotherapeutics. Volume 16:Issue 3(2020)
• Page Start: 523
• Page End: 529
• Publication Date: 2020-03-03
• Subjects: CYD-TDV -- dengue -- Singapore -- booster vaccine -- tetravalent; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2019.1661204
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: The tetravalent dengue vaccine (CYD-TDV; Dengvaxia®) is administered on a three-dose schedule, 6 months apart in those aged ≥9 years in a number of dengue-endemic countries in Asia and Latin America. In this study, CYD63 (NCT02824198), participants aged 9–45 years at first vaccination, and who had received three doses of CYD-TDV in the CYD28 study more than 5 years previously, were randomized 3:1 to receive a booster CYD-TDV dose (Group 1) or placebo (Group 2). Dengue neutralizing antibody geometric mean titres (PRNT50 GMTs) for each of the four dengue serotypes were assessed in sera collected before and 28 days after booster injections. Non-inferiority of the booster immune response versus that induced after the third dose was demonstrated for each serotype if the lower limit of the two-sided 95% confidence interval (CI) was >0.5 for the GMT ratios (GMTRs) between post-booster CYD-TDV dose and post-dose 3 in Group 1. Overall, 118 participants received CYD-TDV booster or placebo and 116 (98.3%) completed the study; two participants were withdrawn because of noncompliance. GMTs in the booster CYD-TDV group increased across all serotypes post-booster injection by 1.74- (serotype 1) to 3.58-fold (serotype 4). No discernible increases were observed in the placebo group. Non-inferiority was demonstrated for serotypes 1, 3, and 4, but not for serotype 2 (GMTR; 0.603 [95% CI, 0.439– 0.829]). No safety issues were observed. These data show that the CYD-TDV booster given 5 or more years later tended to restore GMTs back to levels observed post-dose 3.